| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/34859955_HAS_TOPIC_C0003250> <https://research.tib.eu/covid-19/entity/34859955_HAS_TOPIC_C0013059> <https://research.tib.eu/covid-19/entity/34859955_HAS_TOPIC_C0013072> <https://research.tib.eu/covid-19/entity/34859955_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/34859955_HAS_TOPIC_C0086582> <https://research.tib.eu/covid-19/entity/34859955_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/34859955_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'CSL Limited, Parkville, Victoria, Australia.\', \'CSL Behring Innovation GmbH, Marburg, Germany.\', \'CSL Behring, King of Prussia, Pennsylvania, USA.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Feuersenger_Henrike> <https://research.tib.eu/covid-19/entity/Malandkar_Sourabh> <https://research.tib.eu/covid-19/entity/McKenzie_Andrew> <https://research.tib.eu/covid-19/entity/Panousis_Con> <https://research.tib.eu/covid-19/entity/Pawaskar_Dipti> <https://research.tib.eu/covid-19/entity/Roberts_Anthony>
?:doi	10.1111/cts.13180
?:doi	<https://research.tib.eu/covid-19/entity/10.1111/cts.13180>
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Clinical_Trial%2C_Phase_I> <https://research.tib.eu/covid-19/entity/Journal_Article> <https://research.tib.eu/covid-19/entity/Randomized_Controlled_Trial> <https://research.tib.eu/covid-19/entity/Research_Support%2C_Non-U.S._Gov%27t>
?:journal	Clinical and translational science
is ?:pmid of	<https://research.tib.eu/covid-19/entity/34859955>
?:pmid	<https://research.tib.eu/covid-19/entity/34859955>
?:pmid	34859955
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	0.669
?:rankingScore_hIndex	31
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/C1708335_LOCATION_OF_C0003250>
?:title	A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2022

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/34859955>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/34859955>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all